↓ Skip to main content

Dove Medical Press

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report

Overview of attention for article published in Neuropsychiatric Disease and Treatment, November 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 X users

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
21 Mendeley
Title
Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report
Published in
Neuropsychiatric Disease and Treatment, November 2017
DOI 10.2147/ndt.s148616
Pubmed ID
Authors

Kosuke Okazaki, Kazuhiko Yamamuro, Toshifumi Kishimoto

Abstract

Antipsychotics are effective for treating schizophrenia, but atypical antipsychotics can cause several adverse side effects including weight gain, hyperprolactinemia, and extrapyramidal symptoms. Moreover, weight gain increases the risk of metabolic diseases. We treated a case of olanzapine-induced weight gain in a 41-year-old man with schizophrenia by switching his medication from olanzapine to asenapine. The weight gain improved after switching the medication, from 80.3 to 75.0 kg, a weight loss of 6.6%, and there was no significant worsening of psychological symptoms or other adverse effects. Asenapine might be effective for treating patients with schizophrenia who experience olanzapine-induced weight gain.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 21 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 4 19%
Student > Bachelor 4 19%
Student > Doctoral Student 2 10%
Other 1 5%
Unspecified 1 5%
Other 2 10%
Unknown 7 33%
Readers by discipline Count As %
Psychology 2 10%
Nursing and Health Professions 2 10%
Unspecified 1 5%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Veterinary Science and Veterinary Medicine 1 5%
Other 3 14%
Unknown 11 52%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 February 2018.
All research outputs
#16,051,091
of 25,382,440 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,583
of 3,131 outputs
Outputs of similar age
#193,886
of 340,752 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#32
of 64 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,131 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,752 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 64 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.